Mechanism-based corrector combination restores ΔF508-CFTR folding and function

Tsukasa Okiyoneda, Guido Veit, Johanna F. Dekkers, Miklos Bagdany, Naoto Soya, Haijin Xu, Ariel Roldan, Alan S. Verkman, Mark Kurth, A. Simon, T. Hegedűs, Jeffrey M. Beekman, Gergely L. Lukacs

Research output: Article

200 Citations (Scopus)

Abstract

The most common cystic fibrosis mutation, ΔF508 in nucleotide binding domain 1 (NBD1), impairs cystic fibrosis transmembrane conductance regulator (CFTR)-coupled domain folding, plasma membrane expression, function and stability. VX-809, a promising investigational corrector of ΔF508-CFTR misprocessing, has limited clinical benefit and an incompletely understood mechanism, hampering drug development. Given the effect of second-site suppressor mutations, robust ΔF508-CFTR correction most likely requires stabilization of NBD1 energetics and the interface between membrane-spanning domains (MSDs) and NBD1, which are both established primary conformational defects. Here we elucidate the molecular targets of available correctors: class I stabilizes the NBD1-MSD1 and NBD1-MSD2 interfaces, and class II targets NBD2. Only chemical chaperones, surrogates of class III correctors, stabilize human ΔF508-NBD1. Although VX-809 can correct missense mutations primarily destabilizing the NBD1-MSD1/2 interface, functional plasma membrane expression of ΔF508-CFTR also requires compounds that counteract the NBD1 and NBD2 stability defects in cystic fibrosis bronchial epithelial cells and intestinal organoids. Thus, the combination of structure-guided correctors represents an effective approach for cystic fibrosis therapy

Original languageEnglish
Pages (from-to)444-454
Number of pages11
JournalNature Chemical Biology
Volume9
Issue number7
DOIs
Publication statusPublished - júl. 2013

Fingerprint

Cystic Fibrosis Transmembrane Conductance Regulator
Nucleotides
Cystic Fibrosis
Cell Membrane
Organoids
Genetic Suppression
Missense Mutation
Epithelial Cells
Mutation
Membranes

ASJC Scopus subject areas

  • Cell Biology
  • Molecular Biology

Cite this

Okiyoneda, T., Veit, G., Dekkers, J. F., Bagdany, M., Soya, N., Xu, H., ... Lukacs, G. L. (2013). Mechanism-based corrector combination restores ΔF508-CFTR folding and function. Nature Chemical Biology, 9(7), 444-454. https://doi.org/10.1038/nchembio.1253

Mechanism-based corrector combination restores ΔF508-CFTR folding and function. / Okiyoneda, Tsukasa; Veit, Guido; Dekkers, Johanna F.; Bagdany, Miklos; Soya, Naoto; Xu, Haijin; Roldan, Ariel; Verkman, Alan S.; Kurth, Mark; Simon, A.; Hegedűs, T.; Beekman, Jeffrey M.; Lukacs, Gergely L.

In: Nature Chemical Biology, Vol. 9, No. 7, 07.2013, p. 444-454.

Research output: Article

Okiyoneda, T, Veit, G, Dekkers, JF, Bagdany, M, Soya, N, Xu, H, Roldan, A, Verkman, AS, Kurth, M, Simon, A, Hegedűs, T, Beekman, JM & Lukacs, GL 2013, 'Mechanism-based corrector combination restores ΔF508-CFTR folding and function', Nature Chemical Biology, vol. 9, no. 7, pp. 444-454. https://doi.org/10.1038/nchembio.1253
Okiyoneda T, Veit G, Dekkers JF, Bagdany M, Soya N, Xu H et al. Mechanism-based corrector combination restores ΔF508-CFTR folding and function. Nature Chemical Biology. 2013 júl.;9(7):444-454. https://doi.org/10.1038/nchembio.1253
Okiyoneda, Tsukasa ; Veit, Guido ; Dekkers, Johanna F. ; Bagdany, Miklos ; Soya, Naoto ; Xu, Haijin ; Roldan, Ariel ; Verkman, Alan S. ; Kurth, Mark ; Simon, A. ; Hegedűs, T. ; Beekman, Jeffrey M. ; Lukacs, Gergely L. / Mechanism-based corrector combination restores ΔF508-CFTR folding and function. In: Nature Chemical Biology. 2013 ; Vol. 9, No. 7. pp. 444-454.
@article{0d9fa690d815446d89b04a4ce28c568b,
title = "Mechanism-based corrector combination restores ΔF508-CFTR folding and function",
abstract = "The most common cystic fibrosis mutation, ΔF508 in nucleotide binding domain 1 (NBD1), impairs cystic fibrosis transmembrane conductance regulator (CFTR)-coupled domain folding, plasma membrane expression, function and stability. VX-809, a promising investigational corrector of ΔF508-CFTR misprocessing, has limited clinical benefit and an incompletely understood mechanism, hampering drug development. Given the effect of second-site suppressor mutations, robust ΔF508-CFTR correction most likely requires stabilization of NBD1 energetics and the interface between membrane-spanning domains (MSDs) and NBD1, which are both established primary conformational defects. Here we elucidate the molecular targets of available correctors: class I stabilizes the NBD1-MSD1 and NBD1-MSD2 interfaces, and class II targets NBD2. Only chemical chaperones, surrogates of class III correctors, stabilize human ΔF508-NBD1. Although VX-809 can correct missense mutations primarily destabilizing the NBD1-MSD1/2 interface, functional plasma membrane expression of ΔF508-CFTR also requires compounds that counteract the NBD1 and NBD2 stability defects in cystic fibrosis bronchial epithelial cells and intestinal organoids. Thus, the combination of structure-guided correctors represents an effective approach for cystic fibrosis therapy",
author = "Tsukasa Okiyoneda and Guido Veit and Dekkers, {Johanna F.} and Miklos Bagdany and Naoto Soya and Haijin Xu and Ariel Roldan and Verkman, {Alan S.} and Mark Kurth and A. Simon and T. Hegedűs and Beekman, {Jeffrey M.} and Lukacs, {Gergely L.}",
year = "2013",
month = "7",
doi = "10.1038/nchembio.1253",
language = "English",
volume = "9",
pages = "444--454",
journal = "Nature Chemical Biology",
issn = "1552-4450",
publisher = "Nature Publishing Group",
number = "7",

}

TY - JOUR

T1 - Mechanism-based corrector combination restores ΔF508-CFTR folding and function

AU - Okiyoneda, Tsukasa

AU - Veit, Guido

AU - Dekkers, Johanna F.

AU - Bagdany, Miklos

AU - Soya, Naoto

AU - Xu, Haijin

AU - Roldan, Ariel

AU - Verkman, Alan S.

AU - Kurth, Mark

AU - Simon, A.

AU - Hegedűs, T.

AU - Beekman, Jeffrey M.

AU - Lukacs, Gergely L.

PY - 2013/7

Y1 - 2013/7

N2 - The most common cystic fibrosis mutation, ΔF508 in nucleotide binding domain 1 (NBD1), impairs cystic fibrosis transmembrane conductance regulator (CFTR)-coupled domain folding, plasma membrane expression, function and stability. VX-809, a promising investigational corrector of ΔF508-CFTR misprocessing, has limited clinical benefit and an incompletely understood mechanism, hampering drug development. Given the effect of second-site suppressor mutations, robust ΔF508-CFTR correction most likely requires stabilization of NBD1 energetics and the interface between membrane-spanning domains (MSDs) and NBD1, which are both established primary conformational defects. Here we elucidate the molecular targets of available correctors: class I stabilizes the NBD1-MSD1 and NBD1-MSD2 interfaces, and class II targets NBD2. Only chemical chaperones, surrogates of class III correctors, stabilize human ΔF508-NBD1. Although VX-809 can correct missense mutations primarily destabilizing the NBD1-MSD1/2 interface, functional plasma membrane expression of ΔF508-CFTR also requires compounds that counteract the NBD1 and NBD2 stability defects in cystic fibrosis bronchial epithelial cells and intestinal organoids. Thus, the combination of structure-guided correctors represents an effective approach for cystic fibrosis therapy

AB - The most common cystic fibrosis mutation, ΔF508 in nucleotide binding domain 1 (NBD1), impairs cystic fibrosis transmembrane conductance regulator (CFTR)-coupled domain folding, plasma membrane expression, function and stability. VX-809, a promising investigational corrector of ΔF508-CFTR misprocessing, has limited clinical benefit and an incompletely understood mechanism, hampering drug development. Given the effect of second-site suppressor mutations, robust ΔF508-CFTR correction most likely requires stabilization of NBD1 energetics and the interface between membrane-spanning domains (MSDs) and NBD1, which are both established primary conformational defects. Here we elucidate the molecular targets of available correctors: class I stabilizes the NBD1-MSD1 and NBD1-MSD2 interfaces, and class II targets NBD2. Only chemical chaperones, surrogates of class III correctors, stabilize human ΔF508-NBD1. Although VX-809 can correct missense mutations primarily destabilizing the NBD1-MSD1/2 interface, functional plasma membrane expression of ΔF508-CFTR also requires compounds that counteract the NBD1 and NBD2 stability defects in cystic fibrosis bronchial epithelial cells and intestinal organoids. Thus, the combination of structure-guided correctors represents an effective approach for cystic fibrosis therapy

UR - http://www.scopus.com/inward/record.url?scp=84879410121&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879410121&partnerID=8YFLogxK

U2 - 10.1038/nchembio.1253

DO - 10.1038/nchembio.1253

M3 - Article

C2 - 23666117

AN - SCOPUS:84879410121

VL - 9

SP - 444

EP - 454

JO - Nature Chemical Biology

JF - Nature Chemical Biology

SN - 1552-4450

IS - 7

ER -